Ignite Creation Date:
2025-12-25 @ 12:53 AM
Ignite Modification Date:
2026-06-08 @ 7:32 PM
Study NCT ID:
NCT05668767
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-12-30
First Post:
2022-12-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Sponsor:
Beijing Chest Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-12
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2022-12-20
First Submit QC Date:
None
Study First Post Date:
2022-12-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-12-20
Last Update Post Date:
2022-12-30
Last Update Post Date Type:
ACTUAL